Scholarlink

Objective <p>Achieving first-cycle approval in Abbreviated New Drug Applications (ANDAs) is a critical goal in the generic drug industry, as it enables faster market entry. This study covers common areas of deficiency within ANDA submissions that often lead to delays and multiple review cycles. This review also delves into FDA initiatives aimed at improving first-cycle approval rates and case study analysis that assess deficiencies impact on approval timelines.</p> Method <p>A literature-based analysis was conducted, reviewed industry reports, regulatory guidelines, and published articles available on various databases to identify trends in ANDA deficiencies.</p> Result <p>Identifies key areas where applicants frequently fall short, such as incomplete data submissions, inadequate manufacturing, labelling and DMF requirements, and insufficient bioequivalence studies.</p> Conclusion <p>Overall, it provides valuable insights and practical guidance for generic drug developers to refine their submissions, aiming for higher first-cycle approval success in alignment with FDA standards.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Focusing on First Cycle Approval in ANDA Submission: Understanding Common Deficiencies & Case Study Insights

  • 期刊论文

  • 发表日期：

    2025年2月8日

查看全文
  • Jyoti Pawar,
  • Namita Hegde,
  • Sanjay Sharma

摘要

Objective

Achieving first-cycle approval in Abbreviated New Drug Applications (ANDAs) is a critical goal in the generic drug industry, as it enables faster market entry. This study covers common areas of deficiency within ANDA submissions that often lead to delays and multiple review cycles. This review also delves into FDA initiatives aimed at improving first-cycle approval rates and case study analysis that assess deficiencies impact on approval timelines.

Method

A literature-based analysis was conducted, reviewed industry reports, regulatory guidelines, and published articles available on various databases to identify trends in ANDA deficiencies.

Result

Identifies key areas where applicants frequently fall short, such as incomplete data submissions, inadequate manufacturing, labelling and DMF requirements, and insufficient bioequivalence studies.

Conclusion

Overall, it provides valuable insights and practical guidance for generic drug developers to refine their submissions, aiming for higher first-cycle approval success in alignment with FDA standards.